HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

J Lejeune Selected Research

Hematinics

4/2016Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


J Lejeune Research Topics

Disease

2Neoplasms (Cancer)
05/2010 - 08/2004
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2017
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
04/2016
1Glioma (Gliomas)
05/2007
1Glioblastoma (Glioblastoma Multiforme)
09/2006
1Oligodendroglioma
08/2004
1Weight Gain
04/2001
1Cysts
06/2000

Drug/Important Bio-Agent (IBA)

2Temozolomide (Temodar)FDA LinkGeneric
05/2007 - 08/2004
1HematinicsIBA
04/2016
1Lenalidomide (CC 5013)FDA Link
04/2016
1Monoclonal AntibodiesIBA
05/2010
1ErbB Receptors (EGF Receptor)IBA
09/2006
1Amantadine (Aman)FDA LinkGeneric
04/2001
1Olanzapine (Zyprexa)FDA Link
04/2001

Therapy/Procedure

1Transplantation
10/2017
1Drug Therapy (Chemotherapy)
05/2007
1Therapeutics
04/2001
1Operative Surgical Procedures
06/2000